AbCellera Results Presentation Deck

Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 8 EXPAND CAPABILITIES AGAINST TARGETS DIFFICULT-TO-DRUG WITH ACQUISITION OF TETRAGENETICS GPCR and ion channel proteins are high value, difficult-to-drug targets. Integrating TetraGenetics into our tech stack provides an optimized source of proteins for our antibody discovery efforts and solves a key challenge in pursuing these highly sought-after, but difficult-to-drug targets. 000f M Hi!

View entire presentation